DOCSLIB.ORG

BIOTECH in EUROPE INVESTOR FORUM INVESTOR EUROPE in BIOTECH T Back :: WELCOME Next U

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BIOTECH in EUROPE INVESTOR FORUM INVESTOR EUROPE in BIOTECH T Back :: WELCOME Next U WELCOME SPEAKERS 13th Annual BIOTECH IN EUROPE INVESTOR FORUM PRESENTING COMPANIES 30th September – 1st October 2013 Hilton Zurich Airport Hotel, Switzerland Conference Guide SUPPORTING ORGANISATIONS SUPPORTING ORGANISERS www.sachsforum.com BIOTECH IN EUROPE INVESTOR FORUM BIOTECH t WELCOME back :: next u Welcome Sachs Associates are delighted to welcome you to the: 13th Annual SPEAKERS Biotech in Europe Investor Forum 30th September-1st October 2013 Hilton Zurich Airport Hotel, Switzerland Sachs Associates are delighted to welcome you to the 13th Annual Biotech in Europe Investor Forum. Following the success of previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas. PRESENTING COMPANIES This Forum is highly transactional and is comprised of a series of panels and presentations from leading investment, pharmaceutical and biotech companies, each one providing an expert outlook on growth and investment activity in Europe’s Biotech industry. The programme highlights the current issues surrounding the evolving M&A market, the Private Equity & Venture Capital environment and a special session on major trends in Partnering. Plus, this year’s programme features more than 80 company presentations from a range of publicly listed and private life science companies looking to raise finance and/or find partners. General Information The registration desk will be open from 8am on September 30th and from 8am on October 1st although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session. SUPPORTING ORGANISATIONS SUPPORTING Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants. A Networking Lunch will be set up in the Zurich A & B rooms. Coffee stations will be set up in the Zurich A & B rooms and the presentation rooms throughout the event. Request for Presentations Please use the agenda to mark off presentations that you are interested in and email your request to [email protected] after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference. ORGANISERS t WELCOME back :: next :: u Events Diary For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Sian Rodgers on [email protected] SPEAKERS MedTech & Diagnostics Innovations Summit 21st November 2013 • Düsseldorf • Germany The Summit is being held to coincide with the leading annual international tradeshow Medica with its 135,000 visitors and is designed to bring together a specialist audience from leading and growth companies focused on M+A, alliances and Investment. The program will feature keynotes from industry leaders and plenary panels on industry acquisitions; public markets, venture investment and growth, company finance, and diagnostics. The subjects of regulation and reimbursement will also be covered. Apart from the plenary session the program will also feature 20+ public and private company presentations focused on innovation and alliances/investment opportunities. The MedTech & Device and Diagnostics presenting track will cover: Oncology, Cardiovascular, Imaging, Digital Healthcare, PRESENTING COMPANIES Surgical Devices & Implants and Diagnostics. There will be many networking opportunities. There is a 1-to-1 online meeting system with meeting rooms provided. In addition, there will be networking breaks and a conference cocktail reception. Participation will be limited and presentations by invitation. Financial Investors will receive complimentary passes. We plan an audience of 150 -200 delegates. 7th Annual European Life Science CEO Forum For Partnering & Investing 4th – 5th March 2014 • Zurich • Switzerland Back for its seventh year, this exclusive and highly transactional partnering event is a must for companies wishing to meet with their peers, engage with leading investors and forge new ORGANISATIONS SUPPORTING partnerships. Building on the success of this year’s event, the forum will provide an excellent platform to gain insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants. The conference will feature up to 80 presentations by large to mid size pharmaceutical companies looking for strategic alliances/partners. Do not miss out on this great opportunity to meet emerging companies, leading global investors and Big Pharma representatives! 14th Annual Biotech in Europe Investor Forum 7th – 8th October 2014 • Zurich • Switzerland ORGANISERS WELCOME Speakers Alain Huriez, Venture Partner, Advent Venture Partners & Chairman, EPEMED Alain joined Advent in 2012 bringing 22 years of experience in management, drug development and financing in the life t sciences sector, including CEO of TcLand Expression and Neovacs, Associate Partner at Truffle Capital and Vice President back :: at Quintiles. Alain is a medical doctor and holds an MBA and a Masters of Pharmaco-Economics from Paris La Sorbonne SPEAKERS University. Prior to joining the industry, he was head of the emergency room in a large teaching hospital and practiced as a General Practitioner for two years. next Alain has been responsible for several initiatives in Europe within the areas of personalized medicine, biomarkers and high u value diagnostics through his work as chairman of EPEMED, the European Personalised Medicine Association he founded in 2009. As an entrepreneur, he co-founded four French biotechnology companies. Prof. Dr. André Rosenthal, CEO , Signature Diagnostics AG André Rosenthal is founder and CEO of Signature Diagnostics AG, a cancer diagnostic company focused on prognostic and predictive (companion diagnostic) biomarkers in colorectal cancer. The biomarker research of Signature is based on a large prospective, multicenter clinical diagnostic study in colorectal cancer which has recruited more than 7.500 patients of all four UICC stages. Fresh-frozen, FFPE tumour tissue specimens and plasma samples with longitudinal clinical annotation are used for deep sequencing with the aim of developing accurate tumor tissue and plasma based tests. André´s current interest is translational oncology with a focus on developing novel next generation sequencing (NGS) tests PRESENTING COMPANIES based on circulating free DNA from plasma which can be used for monitoring colorectal cancer patients but also for early detection of colorectal cancer. In addition, we develop NGS tests for the prediction of outcome (prognosis) of colorectal cancer patients and for the prediction of response to treatment. Signature Diagnostics has developed a suite of five NGS tests in these indications. Our plasma test OncoDetect is an ultra deep sequencing test if circulating DNA and can be used for monitoring patients with colorectal cancer of stage III and IV. This test was presented at the recent ASCO 2013 meeting. Our prognostic NGS test OncoSelect-III will be presented at the 17th ECCO meeting in September 2013 in Amsterdam. Between 1989-2003 André was a member of the core team involved in the world wide Human Genome Sequencing Project (HUGO), from 1989-93 in Cambridge (UK) with Sydney Brenner and John Sulston, from 1993 in Germany as a professor at the Friedrich Schiller University in Jena (Germany). He was in charge of the German Human Genome Sequencing Project and led the chromosome 21 sequencing project in collaboration with Japanese researchers. His team in Jena also contributed to the sequencing of human chromosome 8 and X. During 1989-2000 he participated in several positional cloning projects of human disease genes including X-linked hydrocephalus, MASA syndrome and X-linked spastic, paraplegia (CRASH syndrome), Turner syndrome, Nijmegen breakage syndrome, tricho-rhino-phalangeal syndrome type I, X-linked congenital stationary night blindness, X-linked retinitis pigmentosa 2, MALT lymphoma, and others. André has authored or co-authored 135 peer reviewed original papers. He is an inventor of many patents and patent applications. SUPPORTING ORGANISATIONS SUPPORTING Anja König, Managing Director, Novartis Venture Fund Anja is active in Switzerland and Europe and also responsible for expanding the fund’s presence to Asia Pacific. Prior to joining Novartis she was an Associate Partner at McKinsey and Company, a global consultancy, where she worked with companies in health care in the US, Europe and Emerging Markets. Anja König is a scientist by training and holds a PhD in physics from Cornell University. Anja serves on the boards of Bicycle, Covagen, Heptares, F2G and Nabriva and works with Destiny, Neomics, Oxagen, PharmAbcine, Polyphor and Qurient Therapeutics. ORGANISERS WELCOME Speakers Bart Wuurman, CEO, Lanthio Pharma BV Bart Wuurman, PharmD, has 25 years of International Pharma and Biotech Industry experience. He gained broad industry t experience, ranging from drug development, product licensing to General Management and fund raising with Organon, back SPEAKERS Medeva, Antisoma, DeNovo Pharmaceuticals and AM-Pharma. He was instrumental to raising around e40 million VC e financing and to closing licensing deals worth 700 million. Bart has been a biotech CEO
Load more

Recommended publications
  • Comment Letter
    July 23, 2008 Subject: Follow-up on July 22 Meeting Dr. Sirri et al.: I thank you for meeting with Ken Salomon, John Welborn and me yesterday afternoon to discuss Reg SHO, naked short selling and the SEC's recent emergency order. As a follow-up, I want to emphasize the following points: 1. OSTK continues to believe that it is critical that the SEC extend the pre-borrow requirement of the emergency order to the entire market, not just the 19 select companies. OSTK requests that the SEC promptly undertake swift rulemaking so that this protection applies fairly across the market. 2. OSTK continues to support the prompt and full elimination of the option market maker exception, an exception that swallows up the good intentions of Reg SHO. During yesterday's meeting, we discussed the relationship between the markets for equities and their corresponding derivatives (including listed options). You stated that options market makers enjoy an exception from the Reg SHO requirement that they locate and/or deliver shares when hedging against options positions. I am not sure that I would read Reg SHO to say that. However, under your theory, if an options market maker sells a put with a 6- month expiration, then that same market maker has the legal right to naked short and fail to deliver an equivalent amount of the underlying equity (leaving the option market maker "delta neutral”) for six months. This exception is unnecessary and open to abuse/manipulation, particularly with the married puts that often occur in Reg SHO threshold securities.
    [Show full text]
  • History of Paediatric Treatment in the Reichsuniversität Straßburg (1941-1944) Aisling Shalvey
    History of paediatric treatment in the Reichsuniversität Straßburg (1941-1944) Aisling Shalvey To cite this version: Aisling Shalvey. History of paediatric treatment in the Reichsuniversität Straßburg (1941-1944). His- tory. Université de Strasbourg, 2021. English. NNT : 2021STRAG002. tel-03283700 HAL Id: tel-03283700 https://tel.archives-ouvertes.fr/tel-03283700 Submitted on 12 Jul 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITÉ DE STRASBOURG ÉCOLE DOCTORALE 519 Sciences humaines et sociales – Perspectives européennes [ ARCHE ] THÈSE présentée par : Aisling SHALVEY soutenue le : 12 mars 2021 pour obtenir le grade de : Docteur de l’université de Strasbourg Discipline/ Spécialité : Histoire Contemporaine de la Médecine History of Paediatric Treatment in the Reichsuniversität Straßburg (1941-1944) THÈSE dirigée par : Professeur MAURER Catherine Directrice du thèse, Université de Strasbourg Professeur WEINDLING Paul Directeur du thèse, Oxford Brookes University RAPPORTEURS : Professeur VON BUELTZINGSLOEWEN Isabelle Professor, Université Lumière Lyon 2 Professeur ROELCKE Volker Professor, Justus-Liebig- Universität Gießen AUTRES MEMBRES DU JURY : Professeur BONAH Christian Professor, Université de Strasbourg 1 Do mo sheantuismitheoirí Le grá 2 Acknowledgements I am extraordinarily lucky to have so many people who have supported me throughout the process of writing my PhD thesis; too many people to list, so I will begin by saying thank you to everyone who has helped me along the way.
    [Show full text]
  • Sources 4 Web.Pdf
    SOURCE(S) Cahiers de l’équipe de recherche Arts, Civilisation et Histoire de l’Europe N° 4 - premier semestre 2014 SOURCE(S) Cahiers de l’équipe de recherche Arts, Civilisation et Histoire de l’Europe Directeur de la publication : Nicolas Bourguinat Comité de rédaction : Laurence Buchholzer, Anne Corneloup, Jean-Pascal Gay Numéro coordonné par : Jean-Pascal Gay Secrétariat de rédaction : Laurence Buchholzer, Anne Corneloup, Simone Herry Assistant de rédaction : Guillaume Porte La revue SOURCE(S) est un organe de l’Équipe d’Accueil ARCHE-EA 3400 de l’Université de Strasbourg. Pour les informations sur la revue et les autres activités de l’équipe : www.ea3400.unistra.fr Adresse de la rédaction : Revue SOURCE(S) - Faculté des Sciences Historiques, équipe ARCHE, à l’att. de N. Bourguinat - Palais universitaire - 67084 Strasbourg Cedex - tél. 03 68 85 68 08 courriel : [email protected] Impression : Service imprimerie et reprographie de l’Université de Strasbourg ISSN de la version imprimée : 2265-1306 ISSN du présent support électronique : 2261-8592 SOMMAIRE I. DOSSIER : L’INDIVIDU DANS LES CONFLITS 7 Présentation Jean-Pascal Gay 11 « Que faisais-tu sous l’oligarchie ? » La guerre civile de 404-403 et ses lendemains à Athènes Anne Jacquemin 23 Pierre II de Challes, capitaine armagnac (1409-1436). Renseignement, désinformation et pillage durant la guerre civile Benoît Léthenet 37 Face à l’occupation étrangère de 1815-1818. Les sorties de guerre des Alsaciens Christine Haynes 51 « Un métier de chien que de suivre l’armée ». Prosper Baccuët (1797-1864), peintre militaire au service de l’exploration scientifique de l’Algérie Nicolas Schaub 65 Quand un neutre prend les armes.
    [Show full text]
  • European Biotechnology | Summer Edition | Vol
    I S S N 2 3 6 4 - 2 351 | A 6 0 711 | Interview Hospira’s Paul Greenland talks European about the launch Life Sciences and of the first mAb Industry Magazine biosimilar and the new challenges in Biotechnology Summer Edition 2015 | Volume 14 | 20 € development. Financing European biotech companies have added crowdinvesting to the fi nancing toolbox Nagoya Protocol Poor implementation of benefi t sharing could block Tracking biotech innovation in Europe Antibiotics New EU fi nancing instrument to close funding gap in high- stealthy risk antibiotic development EuroBioFairsCompass The unique guide to the top life killers sciences events in the second half of 2015 FREE EXCERPT Liquid Biopsy 4 CONTENTS European Biotechnology | Summer Edition | Vol. 14 | 2015 FREE EXCERPT COVER STORY INSIGHT EUROPE REGIONAL NEWS 6 European Commission opens 42 Northern Europe: fl oodgates for GM imports Sweden, Denmark, Finland, and Norway 10 First genome-edited crops to be stamped non-GMO by Member 44 Western Europe: States; Heard in Brussels France, Belgium, The Netherlands and the UK 12 European Commission and Euro- pean Investment Bank set to 46 Central Europe: launch new fi nancing instrument Austria, Germany and Switzerland for high-risk antibiotics develop- ment; Horizon2020 call focuses 48 Southern Europe: on personalised medicine; UK lags Italy, Spain, Portugal, Cyprus & Malta behind EU in fi ght against cancer; MEPs demand no dilution of EU life 50 Eastern Europe: sciences rules through TTIP Poland and the Czech Republic ECONOMY PICK & MIX 22 Interview: Paul
    [Show full text]
  • Como Prometió Fidel, En Junio Del 2001, Cuando Dijo: ¡Volverán!, Arribaron Hoy a Nuestra Patria, Gerardo, Ramón Y Antonio.” Raúl
    EDITOR: NOEL GONZÁLEZ GOTERA Nueva Serie. Número 166 Diseño: Lic. Roberto Chávez y Liuder Machado. Semana 131214 - 191214 Foto: Lic. Belkis Romeu e Instituto Finlay La Habana, Cuba. “Como prometió Fidel, en junio del 2001, cuando dijo: ¡Volverán!, arribaron hoy a nuestra Patria, Gerardo, Ramón y Antonio.” Raúl “Desde mi elección como Presidente de los Consejos de Estado y de Ministros, he reiterado en múltiples ocasiones, nuestra disposición a sostener con el gobierno de los Estados Unidos un diálogo respetuoso, basado en la igualdad soberana, para tratar los más diversos temas de forma recíproca, sin menoscabo a la independencia nacional y la autodeterminación de nuestro pueblo… Resultado de un diálogo al más alto nivel, que incluyó una conversación telefónica que sostuve ayer con el Presidente Barack Obama, se ha podido avanzar en la solución de algunos temas de interés para ambas naciones... Esta decisión del Presidente Obama, merece el respeto y reconocimiento de nuestro pueblo. … Proponemos al Gobierno de los Estados Unidos adoptar medidas mutuas para mejorar el clima bilateral y avanzar hacia la normalización de los vínculos entre nuestros países, basados en los principios del Derecho Internacional y la Carta de las Naciones Unidas… Cuba reitera su disposición a sostener cooperación en los organismos multilaterales, como la Organización de Naciones Unidas… Los progresos alcanzados en los intercambios sostenidos demuestran que es posible encontrar solución a muchos problemas… Como hemos repetido, debemos aprender el arte de convivir, de forma civilizada, con nuestras diferencias…“ Raúl Castro Ruz, La Habana, 17 de diciembre de 2014. Fragmentos de su alocución. 1 "Indeed, we've seen the benefits of cooperation between our countries before.
    [Show full text]
  • Cancer Vaccine Therapies: Failures and Future Opportunities Michael D
    Cancer Vaccine Therapies: Failures and Future Opportunities Michael D. Becker, Janet Dally, and Jeffrey Martini, Ph.D. Michael D. Becker President & CEO [email protected] Janet Dally Senior Vice President [email protected] Jeffrey Martini, Ph.D. Vice President [email protected] MD Becker Partners LLC 12 Penns Trail, #231 Newtown, PA 18940 Main phone: 267-756-7094 Email: [email protected] Web: www.mdbpartners.com www.mdbpartners.com Copyright © 2010 MD Becker Partners LLC All rights reserved MD Becker Partners LLC [This page intentionally left blank] Cancer Vaccine Therapies: Failures and Future Opportunities Page 2 MD Becker Partners LLC MD Becker Partners’ reports are limited publications that contain valuable information provided to a select group of customers. Our reports are for our customers’ internal use and not for general publication or disclosure to third parties. No part of this report may be given, lent, resold, or disclosed to non-customers without written permission. Furthermore, no part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the permission of the publisher. For additional information, please refer to Appendix G: Legal Disclaimer. For information regarding permission, write: MD Becker Partners LLC 12 Penns Trail, #231 Newtown, PA 18940 Main phone: 267-756-7094 Email: [email protected] Web: www.mdbpartners.com MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry, including pharmaceuticals, biotechnology, and medical devices. We also work with venture capitalists, institutional investors, and others that provide capital to these companies.
    [Show full text]
  • Annexes 2-3-4-5
    PRÉFET DU BAS-RHIN Direction départementale des territoires Service de l'aménagement durable des territoires Unité de prévention du bruit des transports terrestres dans l'environnement 14 rue du Maréchal Juin - BP 61003 - 67070 STRASBOURG CEDEX Standard téléphonique : 03 88 88 91 00 – Courriel : [email protected].
    [Show full text]
  • Orphan Drug Dummy File
    Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in Sigma-Tau levocarnitine Carnitor 11/15/1989 valproic acid toxicity Pharmaceuticals, Inc. 2 1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving Pediatric thalidomide n/a 9/19/1988 bone marrow transplantation Pharmaceuticals, Inc. 3 A Diagnostic for the management Advanced Imaging Theranost 68 Ga RGD n/a 10/1/2014 of Moyamoya disease (MMD) Projects, LLC (AIP) 4 Cadila heat killed Mycobacterium w Pharmaceuticals immunomodulator Cadi Mw 9/3/2004 Active tuberculosis Limited, Inc. 5 Adjunct to cytokine therapy in the treatment of acute myeloid Histamine Ceplene 12/15/1999 leukemia. EpiCept Corporation 6 Adjunct to surgery in cases of rh-microplasmin, ocriplasmin Jetrea 3/16/2004 pediatric vitrectomy ThromboGenics Inc. 7 Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or Ferring Laboratories, Somatostatin Zecnil 6/20/1988 pancreas. Inc. Page 1 of 377 Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with Allos Therapeutics, efaproxiral n/a 7/28/2004 breast cancer Inc.
    [Show full text]
  • Bodacc Bulletin Officiel Des Annonces Civiles Et
    Quarante-septième année. – No 31 C ISSN 0298-2986 Mercredi 26 juin 2013 BODACCBULLETIN OFFICIEL DES ANNONCES CIVILES ET COMMERCIALES ANNEXÉ AU JOURNAL OFFICIEL DE LA RÉPUBLIQUE FRANÇAISE DIRECTION DE L’INFORMATION Standard......................................... 01-40-58-75-00 LÉGALE ET ADMINISTRATIVE Annonces....................................... 01-40-58-77-56 Accueil commercial....................... 01-40-15-70-10 26, rue Desaix, 75727 PARIS CEDEX 15 Abonnements................................. 01-40-15-67-77 www.dila.premier-ministre.gouv.fr (9 h à 12 h 30) www.bodacc.fr Télécopie........................................ 01-40-58-77-57 BODACC “C” Avis de dépôts des comptes des sociétés Avis aux lecteurs Les autres catégories d’insertions sont publiées dans deux autres éditions séparées selon la répartition suivante Vente et cessions................................................ Créations d’établissements ............................... Procédures collectives ....................................... BODACC “A” Procédures de rétablissement personnel ....... Avis relatifs aux successions ............................ } Modifications diverses........................................ BODACC “B” Radiations ............................................................ } Banque de données BODACC servie par les sociétés : Altares-D&B, EDD, Extelia, Questel, Tessi Informatique, Jurismedia, Pouey International, Scores et Décisions, Les Echos, Creditsafe, Coface services, Cartegie, La Base Marketing,Infolegale, France Telecom Orange, Telino et
    [Show full text]
  • Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All
    2013 MEDICINES IN DEVELOPMENT REPORT Rare Diseases A Report on Orphan Drugs in the Pipeline PRESENTED BY AMERICA’s biopharmACEUTICAL RESEARCH COMPANIES More Than 450 Medicines in Development for Rare Diseases Rare diseases, when taken together, are A major area of this research targets Orphan Drugs in Development* not that rare at all. In fact, according to rare cancers, accounting for more than Application the National Institutes of Health (NIH), one-third of all rare disease medicines in Submitted 30 million Americans have one of the development. Other top research areas Phase III nearly 7,000 diseases that are officially include genetic disorders, neurologi- Phase II deemed “rare” because alone they each cal conditions, infectious diseases and Phase I affect fewer than 200,000 people in autoimmune disorders. the United States. Sometimes, only Despite some recent victories, research a few hundred patients are known to 105 into treatments for rare diseases is a have a particular rare disease. daunting quest. This ongoing innovation Simply receiving a diagnosis of a rare and the hundreds of new medicines in disease often becomes a frustrating development now offer hope that physi- 85 quest, since many doctors may have nev- cians will have new treatment options er before heard of or seen the disease. for patients confronting a rare disease. This is, however, a time of great progress and hope. Biopharmaceutical 65 Contents research is entering an exciting new era Innovative Orphan Drugs with a growing understanding of the in the Pipeline ......................................... 2 human genome. Scientific advances have given researchers new tools to Orphan Drug Approvals ...........................4 explore rare diseases, which are often Challenges in Clinical Trials ......................6 more complex than common diseases.
    [Show full text]
  • Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All
    2013 MEDICINES IN DEVELOPMENT REPORT Rare Diseases A Report on Orphan Drugs in the Pipeline PRESENTED BY AMERICA’s biopharmACEUTICAL RESEARCH COMPANIES More Than 450 Medicines in Development for Rare Diseases Rare diseases, when taken together, are A major area of this research targets Orphan Drugs in Development* not that rare at all. In fact, according to rare cancers, accounting for more than Application the National Institutes of Health (NIH), one-third of all rare disease medicines in Submitted 30 million Americans have one of the development. Other top research areas Phase III nearly 7,000 diseases that are officially include genetic disorders, neurologi- Phase II deemed “rare” because alone they each cal conditions, infectious diseases and Phase I affect fewer than 200,000 people in autoimmune disorders. the United States. Sometimes, only Despite some recent victories, research a few hundred patients are known to 105 into treatments for rare diseases is a have a particular rare disease. daunting quest. This ongoing innovation Simply receiving a diagnosis of a rare and the hundreds of new medicines in disease often becomes a frustrating development now offer hope that physi- 85 quest, since many doctors may have nev- cians will have new treatment options er before heard of or seen the disease. for patients confronting a rare disease. This is, however, a time of great progress and hope. Biopharmaceutical 65 Contents research is entering an exciting new era Innovative Orphan Drugs with a growing understanding of the in the Pipeline ......................................... 2 human genome. Scientific advances have given researchers new tools to Orphan Drug Approvals ...........................4 explore rare diseases, which are often Challenges in Clinical Trials ......................6 more complex than common diseases.
    [Show full text]
  • MM&M Takes a Detailed Look at Key Products in the Pipeline
    MM&M takes a detailed look at key products in the pipeline, highlighting the most promising with insights and ratings from Ptop analysts, to IPE provide an overall picture of each therapeutic’s potential value INE 2010 uerosto commodo odionul PROVOCAtiVe AGMM&M’s Pipeline 2010 drawsENTS from the best in drug development, profiling 15 agents with the highest approval probability and brightest commercial prospects. These are the prime near-term launch candidates. The report also provides updates on 202 products in a host of therapeutic areas. Marc Iskowitz reports ualitative change, rather than the quantitative kind, marks best hope to replace warfarin. Then there are the upstarts. Patients this year’s biopharmaceutical pipeline. There has been a shift with rare diseases are finally getting drugs specifically approved for Q in categories poised to yield near-term approvals. And while them. According to a new analysis by the Tufts Center for the Study not the goldmine drug marketers were hoping for, analysts expect of Drug Development, the annual rate of new product approvals the 2010 R&D seam to yield some exciting launch prospects in the worldwide for neglected diseases increased from an average of 1.8 months and years ahead. in 1975-99 to 2.6 in 2000-09. Vaccines and antiviral drugs have also Oncology, a well of innovative approvals in years past, has run seen a resurgence, with physicians talking about a possible cure for relatively dry. “In 2000-2001, we saw Avastin, Tarceva, Sutent, Nexa- hepatitis C and a number of vaccines in the pipeline for ailments var, Gleevec—drugs that revolutionized the way we think about from flu to cancer and diabetes.
    [Show full text]